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OBJECTIVE—Fewstudieshaveassessedtheefﬁcacyofcarbohydratecountingintype1diabetes,
and none have validated its efﬁcacy in patients who are treated with continuous subcutaneous
insulin infusion (CSII). The aim of our study was to test the effect of carbohydrate counting on
glycemic control and quality of life in adult patients with type 1 diabetes who are receiving CSII.
RESEARCH DESIGN AND METHODS—Sixty-one adult patients with type 1 diabetes
treated with CSII were randomly assigned to either learning carbohydrate counting (interven-
tion)or estimating pre-meal insulindose intheusualempiricalway(control).Atbaseline and12
and 24 weeks, we measured HbA1c, fasting plasma glucose, BMI, waist circumference, recorded
dailyinsulindose,andcapillaryglucosedata,andadministeredtheDiabetes-SpeciﬁcQuality-of-
Life Scale (DSQOLS) questionnaire.
RESULTS—Intention-to-treat analysis showed improvement of the DSQOLS score related to
diet restrictions (week 24 – baseline difference, P = 0.008) and reduction of BMI (P = 0.003) and
waist circumference (P = 0.002) in the intervention group compared with control subjects. No
changes in HbA1c, fasting plasma glucose, daily insulin dose, and hypoglycemic episodes (,2.8
mmol/L) were observed. Per-protocol analysis, including only patients who continuously used
carbohydratecountingandCSIIduringthestudy,conﬁrmedimprovementoftheDSQOLSscore
and reduction of BMI and waist circumference, and showed a signiﬁcant reduction of HbA1c
(20.35% vs. control subjects, P = 0.05).
CONCLUSIONS—Among adult patients with type 1 diabetes treated with CSII, carbohydrate
counting is safe and improves quality of life, reduces BMI and waist circumference, and, in per-
protocol analysis, reduces HbA1c.
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N
utritional management is a corner-
stone in the management of diabe-
tes, and monitoring of carbohydrate
intake,amajordeterminantofpostprandial
blood glucose, is a key strategy for achiev-
ing good glucose control (1–4).
Some studies have examined the con-
tributionofquantityandtype(i.e.,simple
vs. complex) of carbohydrates in patients
with type 1 diabetes and showed that
the daily insulin requirement is indeed
associated with the amount rather than
the type of daily carbohydrate intake
(4–6).
Over the years, a number of methods
have been proposed to help patients with
diabetes to quantify the carbohydrate
content of a meal in real life, for example,
exchange lists, portion/servings, grams,
glycemic index, and insulin:carbohydrate
ratio (I:CHO) (7–9). Among these, the
I:CHO is considered the most advanced
counting technique, consisting of esti-
mating the grams of carbohydrates in a
meal and then calculating the pre-meal
insulin dose based on this estimation
and an insulin sensitivity measure (8).
Carbohydrate counting was devised in
the 1960s, but it has become widely
usedaspartofintensivediabetesmanage-
mentaftertheDiabetesControlandCom-
plications Trial (DCCT) (10,11).
Although carbohydrate counting is
widely used by patients worldwide, few
studies have validated its efﬁcacy in type
1 diabetes (12,13), and none have vali-
dated its efﬁcacy in adult patients receiv-
ing continuous subcutaneous insulin
infusion (CSII). We designed the current
study with the aim of testing the effect of
carbohydrate counting on glucose con-
trol and quality of life over 24 weeks in
adultpatientswithtype1diabetestreated
with CSII.
RESEARCH DESIGN AND
METHODS—The GIOCAR (contegGIO-
CARboidrati)wasdesignedasaprospective,
randomized,controlled,open-labelclinical
trialwithadurationof24weeks.Thestudy
was approved by the Ethics Committee of
theSanRaffaeleScientiﬁcInstituteinMilan
and was registered at ClinicalTrials.gov
(no.NCT01173991).Afterhavingreceived
detailed information about the study and
before any study procedure, participants
signed a written informed consent.
We recruited adult patients with type
1 diabetes treated with CSII and followed
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ORIGINAL ARTICLEat the CSII Outpatient Clinic of the San
Raffaele Scientiﬁc Institute in Milan. We
included patients with type 1 diabetes,
aged 18–65 years, who had been treated
with CSII for .3 months. Exclusion cri-
teriawereserumcreatinine.124mmol/L
inwomenand.150mmol/Linmen,pre-
vious training in carbohydrate counting,
celiac disease, pregnancy, severe comor-
bidities, and any disability preventing
compliance withstudy procedures. Three
diabetologists with experience in manag-
ingpatientsonCSII andtrainedincarbo-
hydrate counting and one dietitian
certiﬁed in carbohydrate counting con-
ducted the study. We used the Complete
Guide to Carb Counting (2nd ed.) (14) as a
reference for carbohydrate counting.
Learning carbohydrate counting involves
several steps. The ﬁrst step is keeping a
food diary: complete food records include
day of the week, meal time, amounts of
food, carbohydrate grams for each food,
total carbohydrate grams for the meal or
snack, preprandial and postprandial (2 h
after the start of the meal) blood glucose,
short-acting insulin dose, and physical ac-
tivity. The I:CHO tells how much insulin
is needed to “cover” the amount of carbo-
hydrates eaten and bring blood glucose
level back to pre-meal target (14,15).
This ratio is calculated on the basis of in-
dividual recorded diary data by dividing
the total grams of carbohydrates of a meal
by the number of units of short-acting in-
sulin that were able to hold post-mealglu-
cose excursions within 1.6 mmol/L. The
sensitivityfactororcorrectionfactoriscal-
culatedbydividing1,800bythetotaldaily
insulin requirement (14,15) and corre-
sponds to the glucose lowering obtained
with one unit of short-acting insulin. By
combining the I:CHO and sensitivity fac-
tor, patients are instructed to estimate the
preprandial insulin dose, taking into con-
sideration preprandial blood glucose and
the amount of carbohydrates they plan
to eat.
The primary outcome of the study
was the change in HbA1c at week 24. Sec-
ondary outcomes were the changes of the
following variables at week 24: quality of
life, assessed with the Diabetes-Speciﬁc
Quality-of-LifeScale(DSQOLS)question-
naire (16), BMI and waist circumference,
hypoglycemic events (capillary glucose
2.8 mmol/L), hypoglycemia and hyper-
glycemia risk indexes (low blood glucose
index [LBGI] and high blood glucose in-
dex [HBGI]) (17), total daily insulin dose,
and fasting plasma glucose. Participants
were randomly assigned to two groups
(group 1 intervention, group 2 control
subjects) with a 1:1 ratio. An investigator
without contact with study participants
generated the treatment allocation se-
quence using a computerized random
number generator (Stata, version 10.0;
Stata Corp, College Station, TX). Because
of the type of intervention, blinding was
not possible. Patients were given the
same glucose meter (OneTouch Ultra2;
LifeScan Inc., Milpitas, CA) for self-
monitoring of blood glucose during the
study period and were asked to measure
capillaryglucosesixtimesperday,accord-
ing to American Diabetes Association
Standards of Medical Care (4). Before ran-
domization, all participants attended a
group lesson with the dietitian about the
recommended diet for patients with dia-
betes. After randomization, patients in
group 1 (intervention) were trained on
carbohydrate counting and bolus calcula-
tion in the ﬁrst 12 weeks using the I:CHO
and sensitivityfactorduring fourtoﬁvein-
dividual sessions with the dietitian and a
diabetologist, whereas patients in group 2
(control subjects) continued estimating
theirpre-mealinsulindoseinanempirical
way. HbA1c and fasting plasma glucose
were measured at baseline and after 12
and 24 weeks. At baseline and after 24
weeks, we measured BMI and waist cir-
cumference, recorded total daily insulin
dose,andaskedpatientstocompleteaval-
idated instrument for assessing diabetes-
speciﬁc quality of life (DSQOLS) (16).
Capillary glucose measurements were
downloaded from the memory of glucose
meters at 12 and 24 weeks at the time of
the outpatient visits, and LBGI and HBGI
were calculated as reported (17). Study
datawererecordedonapaperCaseReport
Form and then entered in a dedicated
database maintained in Microsoft Ofﬁce
Access (Microsoft Corp., Redmond, WA),
and de-identiﬁed datasets were extracted
for statistical analyses. HbA1c was measured
using ion-exchange high-performance
liquid chromatography (DCCT-certiﬁed
method) (18), with a normal range of
3.5–6.0%.
Statistical analysis
The intention-to-treat (ITT) analysis in-
cluded all randomized patients who con-
cluded the trial, i.e., 56 patients (28
patients per group). The per-protocol
(PP) analysis included 20 patients in the
carbohydrate counting group and 27
patients in the control group. For this
analysis,weexcludedninepatientsbecause
of discontinuous use of carbohydrate
counting (,75% of the meals) (six partic-
ipants) or shift from CSII to multiple in-
sulin injections for .7 consecutive days
(two participants in the carbohydrate
counting group, one participant in the
control group).
Baseline characteristics of study
participants in the two groups were
compared using the x
2 test, unpaired,
two-tailed t test, or Mann–Whitney two-
sample statistic as appropriate. Changes
from baseline of DSQOLS scores, BMI
and waist circumference, total daily insu-
lin dose, fasting plasma glucose, LBGI,
and HBGI in the two groups were com-
paredusingtheunpaired, two-tailed ttest
or the Mann-Whitney two-sample statis-
tic, as appropriate. HbA1c levels and hy-
poglycemiceventsduring thestudy inthe
two groups of participants were analyzed
using mixed-effects models.
RESULTS—The clinical trial was car-
ried out between October 2008 and July
2009. The ﬂow diagram of the study is
shown in Fig. 1. Of 67 patients assessed
foreligibility,61wererandomizedand56
concluded the study (28 in each group),
with a dropout rate of 8.2%. Patients as-
signedtogroup1attendedonaverage4.4
(SD 1.13) individual training sessions on
carbohydrate counting.
The baseline characteristics of study
participants are shown in Table 1. The
two groups were similar in age, sex, years
ofschoolcompleted,durationofdiabetes,
duration of CSII, type of insulin used,
daily insulin requirement, and HbA1c
levels.
Metabolic control
In the ITT analysis, HbA1c levels during
the 24 weeks of the study were similar in
the two groups (P = 0.252). However, the
PP analysis showed signiﬁcantly lower
HbA1c levels in the carbohydrate count-
ing group than in control subjects (in-
tervention group 20.4 vs. 20.05% in
control subjects; Δ 20.35%, P = 0.05)
(Fig. 2). BMI change was not a signiﬁ-
cant predictor of HbA1c.N od i f f e r e n c e s
between groups were observed in total
daily insulin dose, LBGI, HBGI, and
fasting plasma glucose levels (data not
shown).
Anthropometrics
The median changes in BMI and waist
circumference for the two groups are
shown in Table 2. Among patients in the
carbohydrate counting group, we ob-
served a signiﬁcant reduction in BMI
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control subjects. The signiﬁcant differ-
ence in BMI and waist circumference per-
sisted in the PP analysis (BMI: P = 0.020;
waist circumference: P = 0.007).
Quality of life
T h em e d i a nc h a n g e si nt h es c o r ef o rt h e
sevensectionsoftheDSQOLSinstrument
between the two groups are shown in
Table 2. Baseline scores were similar in
the two groups of participants. At week
24, we observed a signiﬁcant increase
(meaning a better quality of life) in the
scores related to diet restrictions among
participants in the carbohydrate counting
g r o u pc o m p a r e dw i t hc ontrol subjects.
The signiﬁcant difference in the diet re-
strictionsscorebetweenthetwogroupsof
participants persisted in the PP analysis
(P = 0.004).
Adverse events
The frequency of hypoglycemic events
(i.e., capillary glucose 2.8 mmol/L) was
similar in the two groups in both the ITT
andthePPanalyses.Noepisodesofsevere
hypoglycemia requiring assistance from a
third party were observed during the
study. One patient in the control group
was diagnosed with painful diabetic neu-
ropathy during the study.
CONCLUSIONS—This study reports
the results of the ﬁrst randomized clinical
trial testing the effects of carbohydrate
counting in adult patients with type 1
diabetes treated with CSII. Carbohydrate
counting improved the DSQOLS score
related to diet restrictions and was associ-
ated with a modest, although signiﬁcant,
decrease in BMI and waist circumference.
When patients who did not continuously
use carbohydrate counting or CSII during
thestudywereexcludedfromtheanalyses,
carbohydrate counting was also associated
with a signiﬁcant reduction of HbA1c not
accompanied by an increase of hypoglyce-
mic events.
Patientswithtype1diabetesmustcon-
tinuously match capillary glucose levels,
food intake, and physical activity with
theadministrationoftheappropriatedose
of exogenous insulin to maintain glucose
levels within the recommended target (4).
Dietary restrictions and the stress associ-
ated with the daily management of diabe-
tes have a negative impact on the quality
of life of these patients (19). Carbohy-
dratecountingisatoolthathelpspatients
to estimate in a systematic way the
amount of the pre-meal insulin bolus to
minimize the glucose increase after a
meal,andifnecessary,tocorrectaneither
inappropriatelyhighorlowpre-mealglu-
cose level.
The improvement of the DSQOLS
score related to diet restrictions that we
observed in our study extends previous
ﬁndings by Trento et al. (12) to patients
with type 1 diabetes treated with CSII,
although we did not observe an improve-
ment in HbA1c with carbohydrate count-
ing in our ITT analysis, possibly because
our study was relatively short (6 months)
or not all participants trained in carbohy-
drate counting used it. However, when
only patients who continuously used car-
bohydrate counting for the daily manage-
ment of their diabetes were included in
the analyses, we observed a signiﬁcant
improvement in HbA1c (20.35%) com-
p a r e dw i t hc o n t r o ls u b j e c t s .T h ef a c t
that one of ﬁve participants who learned
carbohydrate counting did not use it to
estimate their meal boluses suggests
that, although relatively simple, this
method may be difﬁcult to implement
for a non-negligible proportion of pa-
tients with type 1 diabetes.
In our study, the observed improve-
mentinmetaboliccontrolamongpatients
using carbohydrate counting in the daily
managementoftheirdiabeteswasachieved
without the increase of body weight,waist
Figure 1—Flow diagram for the GIOCAR trial.
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cemic events usually reported with inten-
sive diabetes management (10,20). Indeed,
in the carbohydrate counting group we
unexpectedly observed a small, although
signiﬁcant, weight loss, for which we have
noobviousexplanation.Atbaseline,allran-
domized patients attended a group lesson
with the dietitian about the recommended
dietforpatientswithdiabetes,withtheonly
difference between the two groups being
learning and using carbohydrate counting.
AdecreaseinBMIwithcarbohydratecount-
ing, although not signiﬁcant, also was ob-
served in the study by Trento et al. (21), in
which the control group had similar expo-
sure to the diabetes care team. We suggest
that carbohydrate counting may provide
users with some additional beneﬁts that fa-
cilitate weight loss, most likely through im-
proved nutrition or increased physical
activity.
Our study has several strengths. First
thesamplesizeisatleastaslargeasthatof
previously published research involving
patients with type 1 diabetes who receive
multipledailyinjections.Second,patients
were provided training in carbohydrate
counting that is feasible in the setting of a
diabetes clinic. On the other hand, our
study has some limitations. First, patients
in the intervention group had more con-
tactwiththediabetescareteamduringthe
teaching of carbohydrate counting, thus
preventing us from ruling out that the
intervention group lost weight and im-
proved metabolic control secondary to
the extra attention, rather than the use of
carbohydrate counting. However, several
evidences support a direct effect of car-
bohydrate counting on the improvement
of glucose control: 1) in our study a sig-
niﬁcant improvement in HbA1c was ob-
served only in the PP analysis, which
included only those participants who in-
deed use carbohydrate counting to esti-
mate their meal boluses; 2)as i m i l a r
decrease in HbA1c after learning carbohy-
drate counting was observed in a study
with a control group with similar expo-
sure to the diabetes care team (21);and 3)
the study patients in the control group
were long-term attendants of our CSII
outpatient clinic, making it unlikely
that a transient increase in contact with
the diabetes care team could signiﬁcantly
affect their diet and diabetes manage-
ment.Moreover,ourstudyhasarelatively
short duration, not allowing the assess-
mentofthe effectsofcarbohydrate count-
ing in the long-term, as it would be
desirable for a lifetime intervention. Fi-
nally, we did not measure physical activ-
ity and food intake during the study, not
allowing us to assess their contribution
to weight loss and improved metabolic
control.
In conclusion, our study shows that
offering carbohydrate counting to pa-
tients with type 1 diabetes treated with
Table 1—Baseline characteristics of study participants by the allocated treatment group
(ITT analysis)
Carbohydrate counting
(n =2 8 )
Control subjects
(n =2 8 ) P value
Female participants 13 (46.4%) 19 (67.9%) 0.105
Age (years)* 41.2 6 10.0 39.8 6 9.8 0.601
Years of school completed† 14 (10–18) 13 (13–15.5) 0.840
Duration of diabetes (years)* 21.9 6 11.0 19.8 6 11.7 0.490
Duration of pump therapy (years)† 2( 1 –3) 2 (0–3.5) 0.796
Type of insulin
Glulisine 14 (50.0%) 17 (60.7%) 0.340
Lispro 12 (42.9%) 7 (25.0%)
Aspart 2 (7.1%) 4 (14.3%)
Insulin requirement (IU/day)†
Total 36 (24.5–49) 33 (28.5–39.5) 0.282
Basal 22.5 (15–26) 18.5 (14–22) 0.268
Boluses 15 (10.5–21.5) 12.5 (10–20.5) 0.522
BMI (kg/m
2)† 23.7 (21–25.2) 23.8 (20.8–26.8) 0.670
Waist circumference (cm)† 83 (78.5–91) 78 (74–85.5) 0.194
Glycated hemoglobin (%)*^ 7.9 6 0.9 8.1 6 1.5 0.526
Categorical variables are presented as frequency with percent in parentheses. *Continuous variables with a
normal distribution are presented as mean with SD in parentheses. †Continuous variables that do not have
a normal distribution are presented as median with the interquartile range in parentheses. ^Normal range
3.5–6.0%.
Figure 2—PP analysis: HbA1c levels (mean and 95% CI) in the two study groups during the
GIOCAR trial. The carbohydrate counting group (◆) had signiﬁcantly lower HbA1c levels than
the control group (◇)( P =0 . 0 5 0 ) .
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Carbohydrate counting in patients on CSIICSII improves quality of life related to
diet restrictions and obtains a modest,
although signiﬁcant, decrease in BMI and
waistcircumference.AreductionofHbA1c,
not accompanied by an increase in hypo-
glycemic events, may be expected when
patients continuously use carbohydrate
counting in the daily management of their
diabetes.
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